FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
Gilead (GILD) announced that the FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with ...
Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain types of breast cancer in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea ...
Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain kinds of breast cancer. This drug can interact with some other medications. For example, Trodelvy can interact ...
Hosted on MSN3d
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX GainsIt was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback